Novartis | NVS - Operating Expenses


Novartis reported $9.29B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bausch Health Companies USD 2.08B 41M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
J&J USD 17.83B 388M Jun/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Sanofi EUR 8.98B 1.73B Mar/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Zoetis USD 3.23B 1.68B Mar/2026